ASARM-truncated MEPE and AC-100 enhance osteogenesis by promoting osteoprogenitor adhesion

Journal of Orthopaedic Research

Volumn 26, Issue 9, 2008, Pages 1256-1262

  Sprowson, Andrew P ^a   McCaskie, Andrew W ^a   Birch, Mark A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Matrix extracellular phosphoglycoprotein; MEPE; Osteoblast; Osteogenesis; SIBLING

Indexed keywords

MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; PROTEIN AC 100; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; ALKALINE PHOSPHATASE; GLYCOPROTEIN; MEPE PROTEIN, RAT; PHOSPHOPROTEIN; SCLEROPROTEIN;

ANIMAL CELL; ARTICLE; BONE DEVELOPMENT; BONE MASS; CELL ADHESION; CELL DIFFERENTIATION; CONTROLLED STUDY; IN VITRO STUDY; NONHUMAN; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; RAT; ANIMAL; DRUG EFFECT; METABOLISM; PHYSIOLOGY;

ALKALINE PHOSPHATASE; ANIMALS; CELL ADHESION; EXTRACELLULAR MATRIX PROTEINS; GLYCOPROTEINS; OSTEOBLASTS; OSTEOGENESIS; PHOSPHOPROTEINS; RATS;

EID: 49149124472     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20606     Document Type: Article

References (34)

1. Rowe PSN, de Zoysa PA, Dong R, et al. 2000. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67:54-68.
2. Argiro L, Desbarats M, Glorieux FH, et al. 2001. Mepe, the gene encoding a tumor-secreted protein in oncogenic hypo-phosphatemic osteomalacia, is expressed in bone. Genomics 74:342-351.
3. MacDougall M, Simmons D, Gu TT, et al. 2002. MEPE/OF45, a new dentin/bone matrix protein and candidate gene for dentin diseases mapping to chromosome 4q21. Connect Tissue Res 43:320-330.
4. Gowen LC, Peterson DN, Mansolf AL, et al. 2003. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem 278:1998-2007.
5. Nampei A, Hashimoto J, Hayashida K, et al. 2004. Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone. J Bone Miner Metab 22:176-184.
6. Igarashi M, Kamiya N, Ito K, et al. 2002. In situ localization and in vitro expression of osteoblast/osteocyte factor 45 mRNA during bone cell differentiation. Histochem J 34:255-263.
7. Lu C, Huang S, Miclau T, et al. 2004. Mepe is expressed during skeletal development and regeneration. Histochem Cell Biol 121:493-499.
8. Long JR, Dindot JL, Zebroski H, et al. 1998. A peptide that inhibits hydroxyapatite growth is in an extended conformation on the crystal surface. Proc Natl Acad Sci USA 95:12083-12087.
9. Raj PA, Johnsson M, Levine MJ, et al. 1992. Salivary statherin. Dependence on sequence, charge, hydrogen bonding potency, and helical conformation for adsorption to hydroxyapatite and inhibition of mineralization. J Biol Chem 267:5968-5976.
10. Hayashibara T, Hiraga T, Yi B, et al. 2004. A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo. J Bone Miner Res 19:455-462.
11. Nagel DE, Khosla S, Sanyal A, et al. 2004. A fragment of the hypophosphatemic factor, MEPE, requires inducible cyclooxygenase-2 to exert potent anabolic effects on normal human marrow osteoblast precursors. J Cell Biochem 93: 1107-1114.
12. Campos M, Couture C, Hirata IY, et al. 2003. Human recombinant endopeptidase PHEX has a strict S1′ specificity for acidic residues and cleaves peptides derived from fibro-blast growth factor-23 and matrix extracellular phosphoglycoprotein. Biochem J 373:271-279.
13. Rowe PSN, Kumagai Y, Gutierrez G, et al. 2004. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34:303-319.
14. Rowe PS, Garrett IR, Schwarz PM, et al. 2005. Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP). Bone 36:33-46.
15. Bokhari MA, Akay G, Zhang S, et al. 2005. The enhancement of osteoblast growth and differentiation in vitro on a peptide hydrogel - PolyHIPE Polymer hybrid material. Biomaterials 26:5198-5208.
16. Ruoslahti E, Pierschbacher MD. 1987. New perspectives in cell adhesion: RGD and integrins. Science 238:491-497.
17. Altroff H, van der Walle CF, Asselin J, et al. 2001. The eighth FIII domain of human fibronectin promotes integrin alphaö-betal binding via stabilization of the ninth FIII domain. J Biol Chem 276:38885-38892.
18. Han JY, Kim HS, Lee SH, et al. 2003. Immunohistochemical expression of integrins and extracellular matrix proteins in non-small cell lung cancer: correlation with lymph node metastasis. Lung Cancer 41:65-70.
19. Plow EF, Haas TA, Zhang L, et al. Ligand binding to integrins. J Biol Chem 275:21785-21788.
20. Syrokou A, Tzanakakis G, Tsegenidis T, et al. 1999. Effects of glycosaminoglycans on proliferation of epithelial and fibro-blast human malignant mesothelioma cells: a structure-function relationship. Cell Prolif 32:85-99.
21. Coussen F, Choquet D, Sheetz MP, et al. 2002. Trimers of the fibronectin cell adhesion domain localize to actin filament bundles and undergo rearward translocation. J Cell Sci 115:2581-2590.
22. Chen CS, Mrksich M, Huang S, et al. 1997. Geometric control of cell life and death. Science 276:1425-1428.
23. McBeath R, Pirone DM, Nelson CM, et al. 2004. Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev Cell 6:483-495.
24. Hughes S, El Haj AJ, Dobson J. 2005. Magnetic micro- and nanoparticle mediated activation of mechanosensitive ion channels. Med Eng Phys 27:754-762.
25. Biggs MJ, Richards RG, Gadegaard N, et al. 2007. Regulation of implant surface cell adhesion: characterization and quantification of S-phase primary osteoblast adhesions on biomimetic nanoscale substrates. J Orthop Res 25:273-282.
26. Dalby MJ, Gadegaard N, Tare R, et al. 2007. The control of human mesenchymal cell differentiation using nanoscale symmetry and disorder. Nat Mater 6:997-1003.
27. Fukai F, Takahashi H, Habu Y, et al. 1996. Fibronectin harbors anticell adhesive activity. Biochem Biophys Res Commun 220:394-398.
28. Miura S, Kamiya S, Saito Y, et al. 2007. Antiadhesive sites present in the fibronectin type III-like repeats of human plasma fibronectin. Biol Pharm Bull 30:891-897.
29. Nagel DE, Khosla S, Sanyal A, et al. 2004. A fragment of the hypophosphatemic factor, MEPE, requires inducible cyclo-oxygenase-2 to exert potent anabolic effects on normal human marrow osteoblast precursors. J Cell Biochem 93:1107-1114.
30. Zaric J, Ruegg C. 2005. Integrin-mediated adhesion and soluble ligand binding stabilize COX-2 protein levels in endothelial cells by inducing expression and preventing degradation. J Biol Chem 280:1077-1085.
31. Scutt A, Bertram P. 1995. Bone marrow cells are targets for the anabolic actions of prostaglandin E2 on bone: induction of a transition from nonadherent to adherent osteoblast precursors. J Bone Miner Res 10:474-487.
32. Scutt A, Zeschnigk M, Bertram P. 1995. PGE2 induces the transition from non-adherent to adherent bone marrow mesenchymal precursor cells via a cAMP/EP2-mediated mechanism. Prostaglandins 49:383-395.
33. Shamir D, Keila S, Weinreb M. 2004. A selective EP4 receptor antagonist abrogates the stimulation of osteoblast recruitment from bone marrow stromal cells by prostaglandin E2 in vivo and in vitro. Bone 34:157-162.
34. Weinreb M, Shamir D, Machwate M, et al. 2006. Prostaglandin E2 (PGE2) increases the number of rat bone marrow osteogenic stromal cells (BMSC) via binding the EP4 receptor, activating sphingosine kinase and inhibiting caspase activity. Prostaglandins Leukot Essent Fatty Acids 75:81-90.